Iovance Biotherapeutics (NasdaqGM:IOVA) faced a challenging week, experiencing a share price decrease of 45% following the release of disappointing Q1 2025 financial results and a significant downward ...

A downtrend has been apparent in Calidi Biotherapeutics, Inc. (CLDI) lately. While the stock has lost 14% over the past two ...

In a Phase Ia trial in ovarian cancer, a strong neutralizing antibody response correlated with better disease control and ...

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) ...

Fintel reports that on May 16, 2025, UBS downgraded their outlook for Iovance Biotherapeutics (NasdaqGM:IOVA) from Buy to ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) and reminds investors ...

Iovance interim president and CEO Frederick Vogt blamed the lower-than-expected Q1 revenue on "a significant reduction in ...

BETHESDA, Md. (AP) — BETHESDA, Md. (AP) — Northwest Biotherapeutics Inc. (NWBO) on Thursday reported a loss of $19.3 million in its first quarter. On a per-share basis, the Bethesda, Maryland-based ...

Our free stock report includes 3 warning signs investors should be aware of before investing in Atara Biotherapeutics. Read for free now. Revenue exceeded analyst estimates significantly. Earnings per ...

Iovance Biotherapeutics, Inc.’s IOVA share price has dipped by 39.12%, which has investors questioning if this is right time ...

Iovance management expects a rebound in Q2 with resumed full manufacturing capacity and increased commercial infusions. Read ...